Optibrium receives further investment from Kester Capital

Optibrium receives further investment from Kester Capital   Second round of funding from existing investors will further drive company expansion and commercial growth of its AI-enabled drug discovery technology. CAMBRIDGE, UK, 21 June 2022 – Optibrium™, a developer of...

Optimising Operations & Processes in Biotech Labs

Optimising Operations & Processes in Biotech Labs Recent developments in computational tools and how these can solve operational challenges in biotech labs. Interview published by Lab Manager: – Biotechnology labs face many challenges, such as operations and...
Inspyra

Inspyra

Inspyra This worked example uses Inspyra™ to interactively explore optimisation strategies to achieve a selective inhibitor of DPP-4 with appropriate physicochemical properties. Starting from a data set of compounds representing three chemical series based on...
Perfecting the use of imperfect QSAR models

Perfecting the use of imperfect QSAR models

Perfecting the use of imperfect QSAR models In this webinar, we examine the effective use of QSAR modelling in drug discovery and discuss a variety of pain points for medicinal chemists in knowing when a model can be trusted and how to avoid common pitfalls. We...